Abstract
Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.
MeSH terms
-
Administration, Oral
-
Animals
-
Binding Sites
-
Cartilage / drug effects
-
Cartilage / metabolism*
-
Chromatography, High Pressure Liquid
-
Enzyme-Linked Immunosorbent Assay
-
Humans
-
Hydroxamic Acids*
-
In Vitro Techniques
-
Kinetics
-
Matrix Metalloproteinase Inhibitors*
-
Models, Chemical
-
Protease Inhibitors / pharmacology*
-
Pyrazines*
-
Rabbits
-
Rats
-
Recombinant Proteins / antagonists & inhibitors
-
Structure-Activity Relationship
-
Substance P / metabolism
-
Sulfonamides
Substances
-
CGS 27023A
-
Hydroxamic Acids
-
Matrix Metalloproteinase Inhibitors
-
Protease Inhibitors
-
Pyrazines
-
Recombinant Proteins
-
Sulfonamides
-
Substance P